ClinicalTrials.Veeva
Menu

Find clinical trials for Asthma in Indianapolis, IN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Pulmonary Eosinophilia
Chronic Obstructive Pulmonary Disease
Obstructive Lung Diseases
Allergic Rhinitis
Nasal Polyps
Respiration Disorders
Respiratory Tract Diseases

Asthma trials near Indianapolis, IN, USA:

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma. (EXHALE-2)

This study will assess the efficacy and safety of dexpramipexole as an adjunctive oral therapy in participants with inadequately controlled asthma...

Enrolling
Asthma
Asthma; Eosinophilic
Drug: Placebo
Drug: Dexpramipexole Dihydrochloride

Phase 3

Areteia Therapeutics

Elwood, Indiana, United States and 125 other locations

This study will assess the effects of benralizumab on airway dynamics in severe eosinophilic asthma in terms of quantitative computed tomogr...

Active, not recruiting
Asthma
Combination Product: Benralizumab

Phase 4

AstraZeneca
AstraZeneca

Greenwood, Indiana, United States and 33 other locations

28-week Phase 3 Efficacy and Safety Study of Tezepelumab in Reducing Oral Corticosteroid Use in Adults with Oral Corticosteroid Dependent Asthma...

Enrolling
Asthma
Other: Placebo
Biological: Tezepelumab

Phase 3

AstraZeneca
AstraZeneca

Bloomington, Indiana, United States and 121 other locations

The purpose of this study is to evaluate dexpramipexole as an add-on oral therapy in participants with inadequately controlled eosinophilic asthma...

Enrolling
Asthma Attack
Asthma; Eosinophilic
Drug: Placebo
Drug: Dexpramipexole Dihydrochloride

Phase 3

Areteia Therapeutics

Elwood, Indiana, United States and 117 other locations

and safety of Atuliflapon administered once daily over a 12-week treatment period to adult participants with moderate to severe uncontrolled asthma...

Enrolling
Asthma
Drug: Atuliflapon
Drug: Placebo

Phase 2

AstraZeneca
AstraZeneca

Indianapolis, Indiana, United States and 353 other locations

MDI), both administered as needed, on the annualized rate of severe asthma exacerbations in adolescents with a documented clinical diagnosis...

Enrolling
Asthma
Combination Product: BDA MDI
Combination Product: AS MDI

Phase 3

AstraZeneca
AstraZeneca

Indianapolis, Indiana, United States and 24 other locations

variable length study to evaluate the efficacy and safety of budesonide/glycopyrronium/formoterol inhaler in adults and adolescents with severe asthma...

Enrolling
Asthma
Drug: BFF pMDI 320/9 μg
Drug: BFF MDI 320/9.6 μg

Phase 3

AstraZeneca
AstraZeneca

Indianapolis, Indiana, United States and 479 other locations

decline in adult patients with uncontrolled moderate to severe asthma.The estimated duration is 4±1 weeks of screening and run-in period, fo...

Enrolling
Asthma
Drug: Placebo
Drug: Dupilumab

Phase 4

Sanofi
Sanofi

Indianapolis, Indiana, United States and 214 other locations

The purpose of the study is to evaluate effect of benralizumab on structural and lung function changes in severe eosinophilic asthmatics.Changes will...

Enrolling
Asthma
Biological: Benralizumab
Biological: Placebo

Phase 4

AstraZeneca
AstraZeneca

Indianapolis, Indiana, United States and 44 other locations

This study will assess the efficacy and safety of daily OM-85 treatment compared to placebo in children aged 6 months to 5 years with recurrent wheez...

Enrolling
Wheezing Lower Respiratory Illness
Recurrent Wheezing
Drug: Placebo
Drug: OM-85

Phase 2

OM Pharma

Indianapolis, Indiana, United States and 30 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems